oalib

OALib Journal期刊

ISSN: 2333-9721

费用:99美元

投稿

时间不限

( 2026 )

( 2025 )

( 2024 )

( 2023 )

自定义范围…

匹配条件: “Chinese Clinical Trial Registry Center” ,找到相关结果约1000条。
列表显示的所有文章,均可免费获取
第1页/共1000条
每页显示 条
基于ChiCTR的经皮耳迷走神经刺激疗法的试验注册现状分析
Analysis of the Current Status of Trial Enrollment for ChiCTR-Based Transcutaneous Auricular Vagus Nerve Stimulation Therapy
 [PDF]

黎岚萍, 肖凌勇, 王璨, 赵世情, 魏响成, 戴晓矞
Traditional Chinese Medicine (TCM) , 2026, DOI: 10.12677/tcm.2026.151023
Abstract: 目的:通过分析中国临床试验注册中心(Chinese Clinical Trial Registry, ChiCTR)登记注册的经皮耳迷走神经刺激(transcutaneous auricular vagus nerve stimulation, taVNS)疗法的临床试验,探究taVNS的临床研究现状及发展趋势。方法:检索从建库至2025年8月31日登记注册的taVNS临床试验,采用Excel 2019建立数据库进行数据分析,归纳、总结taVNS临床试验的现状及发展趋势。结果:研究共纳入204项taVNS的临床试验,包括202项干预性研究和2项观察性研究,国内注册地区涉及20个省级行政区120家注册机构,分布最多的三个地区分别是江苏、浙江和北京,经费来源主要是地方财政和自筹为主,研究病种以术后综合征、脑血管病及其后遗症、胃肠道疾病、疼痛和睡眠障碍为主,151项研究使用了盲法。结论:我国taVNS疗法临床试验注册数量呈上升趋势,近几年研究者对taVNS疗法的重视程度越来越高,但也存在地区发展欠均衡、研究者在盲法的表达上不够具体、注册信息填写欠规范等问题。
Objective: To investigate the current status and development trends of transcutaneous auricular vagus nerve stimulation (taVNS) through analyzing clinical trials registered in the Chinese Clinical Trial Registry (ChiCTR). Methods: We retrieved taVNS trials registered from the registry’s inception to August 31, 2025. Data analysis was conducted using a database created in Microsoft Excel 2019 to summarize the current status and development trends of taVNS clinical trials. Results: The study included 204 taVNS clinical trials, comprising 202 interventional studies and 2 observational studies. Domestic registrations spanned 120 institutions across 20 provincial-level administrative regions, with the highest concentrations in Jiangsu, Zhejiang, and Beijing. Funding primarily originated from local government budgets and self-raised funds. Targeted conditions predominantly included postoperative syndromes, cerebrovascular diseases and their sequelae, gastrointestinal disorders, pain, and sleep disorders. Blinding was employed in 151 studies. Conclusion: The number of registered clinical trials for transcutaneous vagus nerve stimulation (taVNS) therapy in China shows an upward trend, reflecting increasing researcher interest in recent years. However, challenges persist, including uneven regional development, insufficient specificity in researchers’ descriptions of blinding methods, and non-standardized completion of registration information.
分层线性模型对中药新药多中心临床试验重复测量数据的分析
何静,刘璐,高莉敏
中国中医药信息杂志 , 2014,
Abstract: 目的 将分层线性模型应用于中药新药多中心临床评价中,对重复测量数据的适用性与可行性进行探究。方法 理论研究部分对分层线性模型的基本概念和原理进行阐述,并对传统统计学方法和分层线性模型应用条件进行比较;实证研究部分采用某中药新药多中心临床试验的具体数据,应用分层线性模型对中医证候积分这一指标进行分析。结果 最终结果分层线性模型将重复测量时间(time)与组别(group)的交互作用(group×time)作为随机变量带入模型,统计结果中组别、重复测量时间和交互作用变量均有统计学意义,交互作用结果t=2.65,P=0.008 1。在整个治疗过程中试验组均值降低8.5分,对照组降低7.47分。治疗结束时,试验组的中医证候积分均值为2.46分,对照组为3.31分,试验组低于对照组。将统计结果结合中医证候积分均值变化趋势可认为,试验组的疗效不低于对照组。结论 通过对比数据要求、应用条件和分析结果,分层线性模型可作为一种有效模型引入中药新药多中心临床评价中
International Comparison of Data from International Clinical Trials Registry Platform-Registered Clinical Trials  [PDF]
Hitoshi Fujii, Keiko Yukawa, Hajime Sato
Health (Health) , 2016, DOI: 10.4236/health.2016.815169
Abstract: Objectives: Our aim was to clarify the study characteristics of countries that have registered clinical trials studies and to calculate the percentage of clinical trials that were registered in each country’s registry, and try to find and evaluate the factors determining that percentage. Design and Methods: The present study is a cross-sectional study using data from clinical trials registered from January 1, 2011, to December 31, 2015. Only countries with more than 2000 registered trials were included for further study. Ten countries met that criterion: United States, Japan, Iran, Australia, New Zealand, China, India, Germany, United Kingdom, and Netherland. The percentage of clinical trials that were registered in each country’s registry was calculated, and the factors determining that percentage were sought and analyzed through an exploratory approach. Results: The chi-squared test of independence indicated that the rate of clinical trial registration significantly differed between countries. From the adjusted standardized residuals, the percentage of clinical trials that were registered in the country of origin was higher in the United States, India, Japan, and Australia/New Zealand than in the European Union and China. Conclusion: The United States requires that informed consent documents for clinical trials contain clinical trial registration numbers from ClinicalTrials.gov, which could be the reason for the extremely high percentage of registered clinical trials (94%). Since the European Union does not have this requirement, clinical trials conducted in the European Union do not have to be registered in the countries in which they are conducted.
Clinical trials in dentistry in India: Analysis from trial registry
S. Gowri,Sridharan Kannan
- , 2017, DOI: 10.4103/2229-3485.203039
Abstract: Evidence-based practice requires clinical trials to be performed. In India, if any clinical trial has to be performed, it has to be registered with clinical trial registry of India. Studies have shown that the report of clinical trials is poor in dentistry. Hence, the present study has been conducted to assess the type and trends of clinical trials being undertaken in dentistry in India over a span of 6 years
Bias-Variation Dilemma Challenges Clinical Trials: Inherent Limitations of Randomized Controlled Trials and Meta-Analyses Comparing Hernia Therapies  [PDF]
U. Klinge, Andreas Koch, D. Weyhe, Enrico Nicolo, R. Bendavid, Anette Fiebeler
International Journal of Clinical Medicine (IJCM) , 2014, DOI: 10.4236/ijcm.2014.513105
Abstract:

Purpose:Evaluation of hernia therapies according to the current rules of Evidence Based Medicine is widely reduced to results of RCTs or meta-analyses. RCTs have been accepted as a most important tool to confirm a superior effect of an intervention. Unfortunately, in hernia surgery, comparisons of RCTs and correspondingly their use in meta-analyses, are not, surprisingly often, able to confirm any significant impact of a specific procedure due to intrinsic restrictions in a multi-causal setting with its web of influences. Methods:Based on our own experiences of clinical studies in surgery, the present article outlines several situations, with their respective reasons, which argue the severe limitations of RCTs and meta-analysis to define an optimum treatment. Results:Meta-analyses accumulate the variations of each trial, which then may cover any clear causal relationship. RCTs usually are dealing with subgroups of standard patients thus excluding the majority of our patients. Low statistical power of current cohort sizes restricts the analysis of subgroups or of effects with low incidences. Simple comparisons of means frequently are hampered by nonlinear relationships to outcome. The relevance of a specific variable is difficult to separate from other influences. The limited surveillance period of studies ignores a delayed change in outcome. Randomization cannot guarantee a standardized patient’s condition. All the arguments have to be considered as a crucial and fundamental consequence of the bias-variance dilemma or principle of uncertainty in medicine, and underline the many limitations of RCTs to evaluate any specific impact of hernia therapies on e.g. infection, pain or recurrence. Conclusions: Many surgical issues cannot be and should not be investigated by RCTs, in particular, if a marked patients’ heterogeneity has to be considered or the low incidences of the outcome readout cannot be addressed with sufficient statistical power without getting lost in the variation mire. Registries with their non-restricted data-acquisition should be regarded as reliable alternatives for postoperative outcome quality surveillance studies.

Rare disease registries: potential applications towards impact on development of new drug treatments
Arantxa Sancho,Caridad Pontes,Charlotte M. W. Gaasterland,Eric Vermeulen,Johanna H. van der Lee,Kit C. B. Roes,Marijke C. Jansen-van der Weide,Roser Vives,Stavros Nikolakopoulos
- , 2018, DOI: 10.1186/s13023-018-0836-0
Abstract: Checklist: what type of information should be included in a RDR to inform clinical trial desig
Impact of blood pressure lowering, cholesterol lowering and their combination in Asians and non
Antonio Dans,Deepak Kamath,Eva Lonn,Hyejung Jung,Jackie Bosch,Jun Zhu,Lisheng Liu,Prem Pais,Salim Yusuf
- , 2019, DOI: 10.1177/2047487318819019
Abstract: There are limited data on the effects of blood pressure and cholesterol lowering in Asians at intermediate risk and no cardiovascular disease. We report an analysis of the effects of blood pressure and cholesterol lowering in Asians enrolled in the Heart Outcomes Prevention Evaluation 3 (HOPE 3) trial. We randomly assigned 6241 Asians and 6464 non-Asians at intermediate risk without cardiovascular disease to candesartan 16?mg/hydrochlorothiazide 12.5?mg or placebo and rosuvastatin 10?mg or placebo. The first co-primary outcome was a composite of cardiovascular disease death, myocardial infarction and stroke. The second co-primary outcome additionally included heart failure, cardiac arrest and revascularisation. Median follow-up was 5.6 years. Reduction in systolic blood pressure was less among Asians (4.3 vs. 7.7?mmHg for non-Asians, P?<?0.0001) mainly due to a lesser effect in Chinese (2.1?mmHg) than in other Asians (7.3?mmHg), reduction in the latter being similar to non-Asians. The effect on the composite outcomes was similar, with no significant benefits from blood pressure lowering for either Asians (Chinese or non-Chinese) or non-Asians. Rosuvastatin reduced low-density lipoprotein cholesterol to a lesser degree in Asians (0.49?mmol/L (–19.1?mg/dL) compared with non-Asians 0.95?mmol/L (?36.7?mg/dL), Pinteraction?<?0.0004). Yet both groups had similar reductions in the two co-primary outcomes. There was no increase in permanent medication discontinuation due to muscle-related symptoms in either group. There was an excess in new diabetes in non-Asians (4.70% rosuvastatin, 3.52% placebo, P?=?0.025) but not in Asians (3.02% rosuvastatin, 4.04% placebo, P?=?0.0342), Pinteraction?=?0021. Candesartan/hydrochlorothiazide had fewer effects in reducing blood pressure in Chinese and rosuvastatin reduced low-density lipoprotein cholesterol to a lesser extent in Asians compared with non-Asians. There was no overall reduction in clinical events with lowering blood pressure in either Asians or non-Asians, whereas there were clear and consistent benefits with lipid lowering in both. Despite extensive analyses, we have no obvious explanation for the observed findings. Future studies need to include larger numbers of individuals from different regions of the world to ensure that the results of trials are applicable globally
An Information System to Support and Monitor Clinical Trial Process
Daniela Luzi,Fabrizio Pecoraro
International Journal of Computer Science & Information Technology , 2013,
Abstract: The demand of transparency of clinical research results, the need of accelerating the process oftransferring innovation in the daily medical practice as well as assuring patient safety and product efficacymake it necessary to extend the functionality of traditional trial registries. These new systems shouldcombine different functionalities to track the information exchange, support collaborative work, manageregulatory documents and monitor the entire clinical investigation (CIV) lifecycle. This is the approachused to develop MEDIS, a Medical Device Information System, described in this paper under theperspective of the business process, and the underlining architecture. Moreover, MEDIS was designed onthe basis of Health Level 7 (HL7) v.3 standards and methodology to make it interoperable with similarregistries, but also to facilitate information exchange between different health information systems.
Scarce quality assurance documentation in major clinical trial registries for approved medicines used in post-marketing clinical trials
Hanneke Dominicus,Jude Nwokike,Julius Mugwagwa,Suzelle Magalie Gombe,Yorokpa Joachim Doua
- , 2019, DOI: 10.1186/s13063-019-3277-8
Abstract: The online version of this article (10.1186/s13063-019-3277-8) contains supplementary material, which is available to authorized users
Efficacy and safety of the compound Chinese medicine SaiLuoTong in?vascular dementia: A randomized clinical trial
Aihong Zhou,Changbiao Chu,Cuibai Wei,Fang Li,Fangyu Li,Fen Wang,Haiqing Song,Hui Xu,Jia He,Junhua Liang,Longfei Jia,Lu Shi,Min Gong,Serge Gauthier,Shanshan Yang,Shuoqi Chen,Wei Qin,Xiumei Zuo,Yi Tang
- , 2018, DOI: 10.1016/j.trci.2018.02.004
Abstract: No licensed medications are available to treat vascular dementia (VaD)
第1页/共1000条
每页显示 条


Home
Copyright © 2008-2020 Open Access Library. All rights reserved.